Once-monthly efimosfermin alfa prescribed for metabolic dysfunction–associated steatohepatitis with F2 and F3 fibrosis ...

Target RWE, a leader in modern clinical evidence generation for complex diseases, today announced its presentations and strategic contributions at the EASL Congress 2025 in Amsterdam, Netherlands.

Completed data collection and achieved database lock for the pivotal Phase 3 trial of Hydronidone in Chronic Hepatitis B ("CHB")-associated liver ...